Humacyte names Jim Mercadante as chief commercial officer

Humacyte Inc. (NASDAQ: HUMA) appointed Jim Mercadante as chief commercial officer, the biotechnology company announced. Mercadante will oversee commercial strategy, sales, marketing and market access as the company expands its Symvess product launch and prepares for potential future commercial indications.

Mercadante brings more than 25 years of experience in healthcare and medical technology industries. He previously served as chief commercial officer at Qure.ai, a provider of AI-powered healthcare solutions, where he led global sales and business development strategy. His career includes senior leadership positions at Abbott, Johnson & Johnson, GE, Terumo and Rapid AI.

The executive has overseen launches of more than 50 products during his career, according to the company's statement. His experience spans medical devices, diagnostics and healthcare technology across U.S. and international markets.

"Jim brings an exceptional combination of deep commercial acumen and a record of proven results across complex healthcare markets," said Laura Niklason, founder and chief executive officer of Humacyte.

Symvess, Humacyte's first FDA-approved product, received approval in December 2024 for treating extremity vascular trauma. The company has expanded access through hospital approvals and inclusion in the U.S. Defense Logistics Agency's Electronic Catalog. Humacyte has also filed a Marketing Authorization Application in Israel for international expansion.

The Durham, North Carolina-based company develops bioengineered human tissues and is conducting late-stage clinical trials for other vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease treatment.

You May Also Be Interested In

• WISeKey names Alexander Hirsch as group chief marketing officer
• Gossamer Bio raises up to $250M in private placement for PAH drug
• Global Interactive Technologies receives Nasdaq non-compliance notice